Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Events
Nov 30, 2023 at 12:30 PM EST
Nov 16, 2023 at 1:30 PM EST